Revision history of "ANTISARSCOV2.: Development and production of anti-SARS-CoV-2 antibodies intended for the investigation of COVID19" (Q2867184)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 March 2024

12 June 2023

23 May 2023

8 November 2022

29 July 2022

  • curprev 04:5804:58, 29 July 2022DG Regio talk contribs 41,414 bytes +25,029 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, da, ro, sv, nl, fr, de, it, pt, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, da, ro, sv,

20 January 2022

17 January 2022

18 December 2021

13 December 2021

4 December 2021

21 October 2021

13 September 2021

7 July 2021

  • curprev 19:1519:15, 7 July 2021DG Regio talk contribs 9,332 bytes +431 Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string
  • curprev 01:1301:13, 7 July 2021DG Regio talk contribs 8,901 bytes +173 Changed label, description and/or aliases in en: translated_label
  • curprev 01:1301:13, 7 July 2021DG Regio talk contribs 8,728 bytes +1,123 Created claim: summary (P836): SICGEN is a company specialised in the production of antibodies. It has ongoing projects related to the current pandemic, involving the production of antibodies that can be used in research, in the production of kits by laboratories and biotechnology companies to assist in the fight against Covid-19., translated_summary

6 July 2021

5 July 2021